Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;11(5):719-33.
doi: 10.2217/fon.14.272.

Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis

Cecilia Arana Yi  1 , Constantine S Tam, Srdan Verstovsek
Affiliations
Review

Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis

Cecilia Arana Yi et al. Future Oncol. 2015.

Abstract

The JAK1 and JAK2 inhibitor ruxolitinib has approved indications in myelofibrosis, a BCR-AB1-negative myeloproliferative neoplasm associated with progressive bone marrow fibrosis and shortened survival. In Phase III clinical studies, ruxolitinib provided rapid and durable improvement of myelofibrosis-related splenomegaly and symptoms irrespective of mutation status, and was associated with a survival advantage compared with placebo or best available therapy. Because of dose-dependent cytopenias, blood count monitoring and dose titration are important to optimize therapy. Specific precautions apply to the treatment of patients with or at risk of serious infections. Discontinuation of ruxolitinib generally leads to symptom return within 1 week. Ruxolitinib also is approved for treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.

Keywords: JAK inhibitor; myelofibrosis; myeloproliferative neoplasm; polycythemia vera; primary myelofibrosis; ruxolitinib; splenomegaly.

PubMed Disclaimer

References

    1. Mesa RA, Green A, Barosi G, Verstovsek S, Vardiman J, Gale RP. MPN-associated myelofibrosis (MPN-MF) Leuk. Res. 2011;35(1):12–13. - PubMed
    1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951. - PubMed
    1. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437–438. - PubMed
    1. Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2013;88(2):141–150. - PubMed
    1. Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2013;88(6):507–516. - PubMed

MeSH terms